Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.

MiMedx logo

MiMedx

Status

Terminated

Conditions

Treatment of Partial Thickness Burns

Treatments

Device: Mepilex Ag
Other: Dehydrated Human Amnion/Chorion Membrane

Study type

Interventional

Funder types

Industry

Identifiers

NCT02765737
EFBUR002

Details and patient eligibility

About

Multicenter, prospective, randomized, controlled feasibility trial to determine the safety and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as compared to Control alone for the treatment of second degree burns (partial thickness burns) as assessed by time to healing and scarring

Full description

Multicenter, prospective, randomized, controlled feasibility trial to determine the safety and effectiveness of Dehydrated Human Amnion Chorion Membrane (dHACM) plus Control as compared to Control alone for the treatment of second degree burns as assessed by time to healing and scarring

Enrollment

23 patients

Sex

All

Ages

12 months to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ll patients enrolled must meet all the following criteria:

Patient with burn injury that meets all of the following requirements:

  • Occurred within the last 48 hours
  • Wound is thermal in nature
  • Partial-thickness burn (burn extends through the epidermis and may penetrate into the dermis)
  • Total body surface area (TBSA) of burn(s) is 2-20% for all subjects
  • Burn area(s) located on smooth, flat surface
  • 2 burn areas, each with a minimum size of 16cm2 (burn areas may be two separate burns or within one large burn, see Section 9.4.2)
  • Age ≥ 12 months and ≤ 70 years

Exclusion criteria

Subjects meeting any of the following criteria will be excluded:

Burns meeting any of the following criteria:

  • Mechanism of injury was electrical, radiation, chemical or frostbite
  • Wound is larger than 200 cm2
  • Clinically infected burn (as judged by the investigator)

Previous or planned treatment of the Burn Area(s) with any of the following:

Biological Skin Substitutes (including Apligraf®, Dermagraft®, etc.)

Patient criteria that will make patient ineligible for enrollment:

  • Ventilator dependence
  • Active malignant disease or patient is less than 1 year disease-free
  • Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days
  • Auto-immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)
  • Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator
  • Presence of any condition that is likely to compromise healing in the judgment of the Investigator
  • Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)
  • Patient has been on any investigational drug(s) or therapeutic device(s) in the last 30 days or any previous enrollment in this study

Allergy or known sensitivity to any of the following:

Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate

Silver

-

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

23 participants in 2 patient groups

Group 1
Active Comparator group
Description:
Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
Treatment:
Other: Dehydrated Human Amnion/Chorion Membrane
Device: Mepilex Ag
Group 2
Active Comparator group
Description:
Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
Treatment:
Other: Dehydrated Human Amnion/Chorion Membrane
Device: Mepilex Ag

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems